Physicians love AI scribes. Has anyone thought to ask patients what they think?

The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies.

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14.